Orca Bio is at the forefront of advancing cell therapy, focusing on developing next-generation treatments that aim to improve patient outcomes while minimizing risks associated with traditional transplant processes. Their lead investigational product, Orca-T, is designed to replace a patient's cancerous blood and immune system with a healthy one, significantly reducing the risk of graft-versus-host disease (GvHD) and other severe side effects. Preliminary results from clinical trials indicate that Orca-T has achieved higher GvHD-free and relapse-free survival rates compared to conventional allogeneic transplant methods, and it is currently undergoing further evaluation in a Phase III pivotal trial to confirm these findings.

In addition to Orca-T, Orca Bio is also developing Orca-Q, a high-precision cell therapy aimed at patients with haploidentical donors, thereby expanding access to cell therapy for those who cannot find a fully matched donor. Early results from Orca-Q's Phase I trial show promising outcomes, including a reduction in acute GvHD and improved survival rates without GvHD. Orca Bio's commitment to innovation in cell therapy not only targets serious blood cancers but also aims to extend its applications to other blood disorders and solid tumor malignancies, reflecting their vision of making life-changing therapies accessible to a broader patient population.

United States

Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one. Our manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling us to create proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy. Our talented team is driven by a passion for science and compassion for patients.

Orca Bio

Company Details